Gilead Sciences Inc is on track to file for regulatory approval of sofosbuvir, its treatment for chronic hepatitis C virus (HCV) infection, starting in mid-2013, the biotech company said on Monday.
Gilead is scheduled to give investors an update on its candidates for HCV treatment at a JPMorgan healthcare conference this week in San Francisco.
The company will discuss new results from an arm of a continuing Phase 2 trial and provide a progress report on a range of Phase 2 and 3 trials evaluating a once-daily fixed-dose combination tablet of the medicines.
(Reporting by Debra Sherman; editing by John Wallace)
Major depression is increasingly recognized as a serious U.S. health problem. Experts are trying to identify at-risk children and adults and treat depression in its earliest stages.